Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Robust Anti-Angiogenic Research

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a next-generation small-molecule inhibitor with high specificity for VEGFR2, PDGFRβ, and FGFR1, enabling potent suppression of tumor angiogenesis and endothelial cell migration (Chen & Feng 2019). Compared to sunitinib and sorafenib, anlotinib achieves lower IC₅₀ values and broader selectivity, making it a preferred tool in mechanistic and translational cancer research (PD-0325901.com). The compound exhibits rapid oral absorption, high plasma protein binding, and tissue distribution to lung, liver, kidney, and tumor, with the ability to cross the blood-brain barrier (APExBIO). Safety profiles reveal a high median lethal dose (LD₅₀ = 1735.9 mg/kg, 14-day oral, rat) and minimal organ/genetic toxicity. APExBIO provides validated Anlotinib (hydrochloride) for research workflows targeting endothelial migration, tube formation, and tyrosine kinase signaling pathway modulation.

Biological Rationale

Angiogenesis is fundamental to tumor growth and metastasis. Vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor β (PDGFRβ), and fibroblast growth factor receptor 1 (FGFR1) are key drivers of angiogenic signaling in cancer models (Chen & Feng 2019). Overexpression and activation of these kinases correlate with increased tumor vascularization, therapy resistance, and poor clinical outcomes. Multi-target tyrosine kinase inhibitors (TKIs) disrupt these pathways, reducing neovascularization and tumor support networks. Anlotinib hydrochloride, as a multi-target TKI, enables simultaneous blockade of VEGFR2, PDGFRβ, and FGFR1, addressing redundancy and compensatory mechanisms in angiogenic signaling. This makes it an essential anti-angiogenic small molecule for mechanistic and translational cancer research, especially in models where single-pathway inhibition yields limited efficacy (AKTPathway – This article extends mechanistic depth compared to the present review by focusing on translational models).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule inhibitor that binds the ATP-binding pockets of receptor tyrosine kinases. It inhibits VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (IC₅₀: 8.7 ± 3.4 nM), and FGFR1 (IC₅₀: 11.7 ± 4.1 nM), resulting in potent blockade of downstream signaling events, including the ERK pathway (APExBIO). This suppression impairs endothelial cell migration and capillary tube formation in in vitro assays, with efficacy demonstrated in EA.hy 926 and other human vascular endothelial cells. Anlotinib also inhibits additional angiogenic kinases (e.g., c-Kit, Met) and shows minimal off-target cytotoxicity at research concentrations. Compared to other TKIs (sunitinib, sorafenib, nintedanib), anlotinib demonstrates broader and more potent inhibitory profiles, particularly relevant for dissecting tyrosine kinase signaling pathways in preclinical oncology research (Prescission – This article benchmarks product performance, while the present review emphasizes mechanistic context).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2-mediated endothelial cell migration with an IC₅₀ of 5.6 ± 1.2 nM in capillary tube formation assays (APExBIO).
• In vivo, anlotinib demonstrates significant tumor angiogenesis inhibition and high tissue accumulation in lung, liver, kidney, heart, and tumor tissues, with the ability to cross the blood-brain barrier (Chen & Feng 2019).
• Compared to sunitinib, sorafenib, and nintedanib, anlotinib yields lower IC₅₀ values against VEGFR2, PDGFRβ, and FGFR1, indicating superior potency (PD-0325901.com).
• Pharmacokinetic studies in rats and dogs show oral bioavailability of 28–58% and 41–77%, respectively, with rapid absorption and high plasma protein binding (93% in humans) (APExBIO).
• Safety assessments indicate a high median lethal dose (LD₅₀: 1735.9 mg/kg, 14-day oral, rat) and no significant organ or genetic toxicity at research-relevant concentrations (Chen & Feng 2019).
• Clinical case reports reveal efficacy in reducing metastatic lymph node size in intra-abdominal desmoplastic small round cell tumor, with manageable side effects (e.g., triglyceridemia, fatigue) (Chen & Feng 2019).

For more advanced translational discussion, see this roadmap article, which expands on experimental design and strategic integration beyond the present focus on atomic facts.

Applications, Limits & Misconceptions

Anlotinib (hydrochloride) is widely used in research applications involving capillary tube formation assays, endothelial cell migration inhibition, and mechanistic signaling studies in cancer models. Its multi-target profile makes it suitable for dissecting the VEGFR2/PDGFRβ/FGFR1 axis in tumor angiogenesis. The compound is not intended for diagnostic or therapeutic use in humans. Notably, its efficacy in research models does not guarantee clinical utility outside controlled preclinical settings.

Common Pitfalls or Misconceptions

• Not for Clinical Use: Anlotinib (hydrochloride) from APExBIO is supplied for scientific research use only, not for diagnostics or medical therapy (APExBIO).
• Concentration-Dependent Effects: Efficacy and selectivity are concentration-dependent; exceeding recommended concentrations increases risk of off-target effects.
• Model Variability: Results from endothelial cell lines (e.g., EA.hy 926) may not fully recapitulate in vivo tumor microenvironments.
• Pharmacokinetics May Differ: Bioavailability and tissue distribution observed in rats/dogs may not extrapolate directly to humans.
• No Single-Pathway Specificity: As a multi-target TKI, anlotinib cannot be used to attribute outcomes to a single kinase pathway without further controls.

Workflow Integration & Parameters

Storage and Preparation: Store Anlotinib (hydrochloride) at -20°C, protected from moisture and light. Prepare fresh solutions for each experiment to ensure stability and reproducibility. Assay Compatibility: Compatible with endothelial cell migration, tube formation, and ERK pathway modulation assays. Concentration ranges for in vitro studies typically span 1–100 nM, with validation in human vascular endothelial cells such as EA.hy 926. Pharmacokinetics: For preclinical modeling, note its rapid oral absorption, high plasma protein binding, and cytochrome P450 (CYP3A)-mediated metabolism. For in vivo studies, tissue distribution analysis should be performed to confirm target engagement. Related Tools: For strategic design of tumor angiogenesis inhibition studies, see this mechanistic review (extends the present article by offering a translational roadmap).

Conclusion & Outlook

Anlotinib (hydrochloride) is a validated, potent multi-target tyrosine kinase inhibitor offering superior selectivity and efficacy for anti-angiogenic cancer research. Its quantitative inhibition of VEGFR2, PDGFRβ, and FGFR1, favorable pharmacokinetic profile, and established safety make it a gold standard for dissecting angiogenic pathways in preclinical studies. For detailed specifications and ordering, refer to the APExBIO product page (SKU C8688). Future research will further elucidate its role in complex tumor models and combinatorial assay systems, advancing the frontier of tyrosine kinase signaling pathway investigation.